REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Cyclopentanohydrophenanthrene Ring System Doai > Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring SystemOxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/07/06 - 20060276443 - 21-substituted progesterone derivatives as new antiprogestational agents in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group ... 12/07/06 - 20060276442 - Methods of female sexual enhancement A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and ... 11/16/06 - 20060258632 - Methods and agents for treating cardiovascular diseases This invention relates to a method and an agent for treating cardiovascular diseases, especially cardiac hypertrophy, wherein said method and agent consist in increasing testosterone concentration in pathological tissues to normal levels or inhibiting and/or eliminating metabolites from testosterone metabolism. The testosterone concentration in pathological tissues can be increased to ... 11/09/06 - 20060252738 - Method for preparing and using water-based steroid pheromone compositions This invention relates to methods of formulating steroid pheromones as novel stable emulsions. These emulsions can be used for administration of the steroid pheromones to living organisms such as humans or pigs in place of current organic solvent or pressurized aerosol formulations that present hazards in both shipping and application. ... 10/19/06 - 20060234993 - Use of androstane derivatives for enhancing physical performance wherein R3 is one of α-OH , β-OH, a mixture of α-OH and , β-OH, and O; and R7 is one of α-OH, β-OH and O. ... 10/19/06 - 20060234992 - Dhea composition and method Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at ... 09/28/06 - 20060217358 - Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof A=hydrogen or together with B a carbon-carbon bond, B=hydrogen, hydroxy or together with A a carbon-carbon bond, C, D, E, F=hydrogen or together with D a carbon-carbon bond, or the one of its addition salts with pharmaceutically acceptable acids, with the exception of a few compounds, as a medicament, use ... 09/28/06 - 20060217357 - Method of achieving accelerated fat loss by administration of a fat loss accelerating agent to a dieting mammal Accelerating fat loss by administering to a dieting mammal the fat loss accelerating agent 7-oxo DHEA or a pro-drug thereof incapable of in vivo conversion to testosterone. ... 08/10/06 - 20060178353 - Medicament for preventing and/or treating mammarycarcinoma, containing a steroidal aromatase inhibitor A method of prophylaxis and/or treatment of mastocarcinoma (i.e., mammary carcinoma) involves the topical application of a therapeutically or prophylactically effective amount of a steroidal aromatase inhibitor locally, and not systemically, to an area of a patient in need of treatment. This local application avoids the side effects associated with ... 08/10/06 - 20060178352 - Use of androgens to reduce the likelihood of acquiring or to treat skin aging Novel methods of treating or reducing the likelihood of acquiring skin diseases due to age-related androgen deficiency, particularly skin atrophy, loss of collagen, loss of elastic fibers, loss of connective tissue, cellulite, and formation of wrinkles, in susceptible warm-blooded animals including humans involving administration of an androgen or/and a sex ... 07/27/06 - 20060166955 - Production process for 16-dehydropregnenoneol and its analogs The present invention relates to a clean process for the degradation of steroidal sapogenin to produce 16-dehydropregnenolone and its analogs. The pure or the crude pseudo steroidal sapogenin, derived from steroidal sapogenin, dissolved in organic solvent, reacts with hydrogen peroxide with or without metal compound and acid as catalyst, and ... 07/13/06 - 20060154909 - 1,4,6-androstatriene-3,17-dione (atd) for therapeutic uses A composition having modified or derivative of 1,4,6-androstatriene-3,17-dione (“ATD”) will improve the health of mammalian subjects. The improvement of health is achieved with the administration of an effective amount of the at least one modified or derivative of 1,4,6-androstatriene-3,17-dione. Particularly, health is improved for a subject suffering with a gynecomastia, ... 07/06/06 - 20060148774 - Hypoglycemic agent A hypoglycemic agent comprising a compound selected from the group consisting of 24-alkylcholestan-3-ones and 24-alkylcholesten-3-ones (for example, 24-alkylcholestan-3-ones, 24-alkylcholestmonoen-3-ones, 24-alkylcholestdien-3-ones, 24-alkylcholesttrien-3-ones, or 24-alkylcholesttetraen-3-ones, preferably 5-campesten-3-one) as an active ingredient. The agent can be used for improvement of hyperglycemia resulting from diseases such as diabetes, and can be used as a ... 05/11/06 - 20060100186 - Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome Compositions and methods for alleviating the symptoms associated with chronic fatigue syndrome and fibromyalgia syndrome are provided. The compositions are based on use of a transdermal gel formulation delivery system for androgens, either alone or in combination with other hormones. ... 01/12/06 - 20060009432 - Use of neurosteroids to treat neuropathic pain Ganaxolone (3α-hydroxy-3β-methyl-5β-pregnan-20-one) and 3α-hydroxy-3β-methyl-5β-pregnan-20-one and their physiologically cleavable esters are useful for treating neuropathic pain. Compositions comprising a pharmaceutically acceptable excipient and an appropriate compound, along with methods for preparing the compositions are disclosed. Also disclosed are articles of manufacture wherein the composition is combine with labeling instructions for treating ... 11/10/05 - 20050250749 - Helix 12 directed pharmaceutical products are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some ... 10/20/05 - 20050234027 - 17alpha-fluorosteroids, pharmaceutical compositions containing 17alpha-fluorosteroids and a method of making them wherein R1 denotes H or methyl; R2 and R3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character ... 10/13/05 - 20050227954 - Hypoglycemic agent A hypoglycemic agent comprising a compound selected from the group consisting of 24-alkylcholestan-3-ones and 24-alkylcholesten-3-ones (for example, 24-alkylcholestan-3-ones, 24-alkylcholestmonoen-3-ones, 24-alkylcholestdien-3-ones, 24-alkylcholesttrien-3-ones, or 24-alkylcholesttetraen-3-ones, preferably 5-campesten-3-one) as an active ingredient. The agent can be used for improvement of hyperglycemia resulting from diseases such as diabetes, and can be used as a ... 10/06/05 - 20050222106 - Drospirenone-containing preparations for transdermal use The pharmaceutical preparation for transdermal administration contains solvent ingredients, such as water and ethanol and/or propanol, and drospirenone. The drospirenone is contained in the preparation in an amount that is not above its saturation solubility in an initial state prior to application to skin. However after application to the skin ... 10/06/05 - 20050222105 - Hormone-based nitrogen monoxide donor compounds and use thereof in obstetrics and gynecology The invention concerns compounds capable of being fixed on hormone receptors and having a nitrogen monoxide donor group, their use for preventing premature births, increasing cervical-dilatation, for use in hormone substitution therapy as anti-hypertensive drug and their therapeutic use for preparing a medicine for use in obstetrics and gynecology. ... 09/15/05 - 20050203073 - Method of treating inflammatory conditions with progesterone or progesterone analogs The present invention provides methods for treating inflammatory conditions, including but not limited to, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and proctitis), other noninfectious, inflammatory conditions of the GI tract (microscopic colitis, allergic eosinophilic gastroenteritis, food allergies, pill induced esophagitis, celiac disease, recurrent polyps, and hemorrhoids), and psoriasis, using ... ### FreshPatents.com Support |